# Eris Lifesciences (ERIS) — Stock analysis > Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/eris ## Current market snapshot - Exchange: NSE - Country: India - Price: ₹1,237 - Change: +0.58% - As of: 2026-11-06 - 1D return: +0.58% - 5D return: +6.97% - 1M return: +7.09% - Latest complete quarter: fy27_q2 ## Faxioms Analysis _As of 2026-11-06_ ### Technical Outlook ERIS (₹1,237.00) is trading in a short-term bullish phase on the daily chart, positioned near the upper end of its 20-day range (+97.8%) and above key moving averages including the 20-period EMA and SMA. The daily trend is established with an ADX of 30.97, supported by a +DI of 21.84 versus -DI of 14.91. However, this immediate strength contrasts with a weaker medium-term structure: the weekly trend remains bearish with price below all major moving averages and Supertrend, while the monthly trend shows mixed signals with price below MAs but above Supertrend. Recent anomalies include a moderate upward move on 2026-11-06 (+0.6%) following extreme volume activity on 2026-10-27 (+8.4% return, 5.07x volume ratio). The stock faces resistance at ₹1,242.10 (0.41% above) and support at ₹1,228.60 (0.68% below). With annualized volatility at 32.8% and a current drawdown of -33.1%, risk remains elevated. A break above ₹1,242.10 could confirm further upside, while a drop below ₹1,228.60 may signal a reversion to the broader weekly downtrend. - Daily trend is bullish (ADX 30.97) with price above 20/50 EMAs and SMAs, but weekly trend remains bearish (price below all MAs and Supertrend). - Price is near 20-day range high (+97.8%); nearest resistance at ₹1,242.10 (0.41% above) and support at ₹1,228.60 (0.68% below). - Recent anomaly on 2026-11-06 showed moderate upward movement (+0.6%), following extreme volume surge on 2026-10-27 (+8.4% return, 5.07x volume ratio). - High volatility (32.8% annualized) and significant drawdown (-33.1%) persist; monitoring for break above ₹1,242.10 or breakdown below ₹1,228.60. - Morning Star - Inside Bar - Doji - Harami - Bullish Engulfing Reversal ### News Context Eris Lifesciences Limited (NSE: ERIS) has filed notices regarding a postal ballot to appoint Mr. Akhil Awasthi as a Non-Executive Independent Director for five years, with e-voting open from November 6 to December 5, 2026. The company also announced an 'Eris Investor Meet - 2026' scheduled for November 19 in Mumbai, noting that discussions will be limited to publicly available information. As of November 6, 2026, the stock closed at ₹1,237.00, reflecting a year-to-date decline of 17.6% and a current drawdown of 33.1%. Technical indicators show mixed signals: daily trends are bullish with resistance near ₹1,242.10, while weekly trends remain bearish. - Corporate Governance: Postal ballot for appointing Mr. Akhil Awasthi as Non-Executive Independent Director is active; e-voting runs from November 6 to December 5, 2026. - Investor Engagement: Physical and virtual investor meet scheduled for November 19, 2026, in Mumbai; no unpublished price sensitive information to be discussed. - Price Action: Stock closed at ₹1,237.00 on November 6, 2026, with immediate resistance at ₹1,242.10 (0.41% above) and support at ₹1,228.60 (0.68% below). - Performance Context: Year-to-date return is -17.6%; annualized volatility stands at 32.8% with a maximum historical drawdown of -40.7%. - Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication - Eris Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting - Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL - Eris Lifesciences Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates - Eris Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates ### Official Filings Eris Lifesciences reported consolidated net profit of ₹187.14 Crores for Q2 FY27 (ended September 30, 2026), a 39.2% increase from the prior year, driven by revenue growth of 12.6% to ₹892.37 Crores. The company executed a significant corporate restructuring via the amalgamation of Aprica Healthcare, Eris Oaknet Healthcare, and Eris Therapeutics, effective October 22, 2026, which generated a ₹96 Crore current tax credit. Operational milestones include regulatory approval for Phase 1 and Phase 3 trials for India’s first Recombinant Semaglutide and the commercialization of the Bhopal facility for insulin vials and cartridges. However, the Domestic Branded Formulations segment saw an EBITDA margin contraction of 191 basis points to 35.7%. Shareholder approval is pending for the five-year appointment of Mr. Akhil Awasthi as Non-Executive Independent Director, with e-voting scheduled from November 6 to December 5, 2026. - Q2 FY27 Consolidated Net Profit: ₹187.14 Crores (+39.2% YoY); Revenue: ₹892.37 Crores (+12.6% YoY). - Corporate Restructuring: Amalgamation of three subsidiaries effective Oct 22, 2026, resulting in a ₹96 Crore current tax credit. - Pipeline & Operations: Received regulatory approval for Phase 1/3 trials for Recombinant Semaglutide; Bhopal facility for insulin vials/cartridges now commercialized. - Margin Pressure: Domestic Branded Formulations EBITDA margin contracted by 191 bps to 35.7% in Q2. - Governance Update: Postal ballot for appointing Mr. Akhil Awasthi as Independent Director runs Nov 6–Dec 5, 2026; approval pending. - [Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/ERIS_06112026144538_Signedintimation_1.pdf) - [Eris Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/ERIS_04112026164053_signedIntimation.pdf) - [Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_15266_WebXMLFile_20261104_164430997.xml) - [Eris Lifesciences Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_29102026171716_intimationsigned.pdf) - [Eris Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_29102026172141_Intimationsigned.pdf) - [Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/ERIS_26102026134804_Signedoutcome.pdf) - [Eris Lifesciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/ERIS_26102026135457_Presentationsigned.pdf) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745950_26102026050920_WEB.xml) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745951_26102026050937_WEB.xml) - [Eris Lifesciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_26102026210145_intimationsigned.pdf) ### Fundamentals Eris Lifesciences demonstrates strong earnings momentum with Net Profit rising to ₹718 crore (TTM) and EPS reaching ₹51.18, supported by robust sales growth of 23% over three years. However, this profitability is accompanied by a significant deterioration in cash conversion efficiency; the Cash Conversion Cycle widened sharply to 129 days as of Mar 2026, driven by higher inventory days (200) and debtor days (79). The balance sheet reflects a strategic shift in capital structure: while total borrowings remain stable around ₹2,430 crore, the composition has moved from non-current to current liabilities, with Current Borrowings jumping to ₹1,954 crore as of Sep 2026. This restructuring coincides with a sharp decline in FII ownership to 5.74%, contrasting with steady promoter holding (~54.7%) and increasing DII participation (20.19%). - Earnings Quality Signal: CFO/EBITDA dropped to 59% in FY2026 from 114% in FY2025, indicating lower operating profit conversion to cash despite high net profit growth. - Liquidity Shift: Current borrowings surged to ₹1,954 crore (Sep 2026) from ₹755 crore (Sep 2025), while non-current borrowings fell to ₹427 crore, altering the debt maturity profile. - Working Capital Pressure: Inventory Days increased to 200 and Debtor Days to 79 as of Mar 2026, contributing to the extended 129-day Cash Conversion Cycle. - Ownership Trend: FIIs reduced stake to 5.74% (Sep 2026) from 8.01% (Sep 2024), while DIIs increased to 20.19%; Promoters maintained ~54.7% holding. ### Bear Case Eris Lifesciences faces significant headwinds as evidenced by its technical setup and recent performance trajectory. The stock is trading at ₹1,237.0, reflecting a substantial year-to-date decline of -17.6% and a one-year return of -22.0%. While the daily trend remains technically bullish with an ADX of 30.97, the weekly trend has turned bearish, marked by a negative EMA-20 slope of -71.37 and a supertrend direction shift to bearish. This divergence suggests that short-term momentum may be losing strength against a broader downward pressure. Risk metrics indicate elevated volatility and downside exposure. The annualized volatility stands at +32.8%, with a current drawdown of -33.1% from peak levels, approaching the historical maximum drawdown of -40.7%. Immediate support is thin, with the nearest pivot level at ₹1,228.6 (0.68% below) and low-level support at ₹1,216.4 (1.67% below). Resistance is also close, with the first hurdle at ₹1,242.1 (0.41% above), limiting upside potential in the near term. Investors should monitor the weekly trend confirmation and price action around these critical support zones for signs of further deterioration. - Weekly trend has shifted to bearish with a steep negative EMA-20 slope (-71.37), contrasting with the daily bullish signal. - Stock is down -17.6% YTD and -22.0% over the past year, with a current drawdown of -33.1% nearing the all-time high of -40.7%. - High volatility (+32.8% annualized) and limited upside room, with immediate resistance just 0.41% above at ₹1,242.1. - Critical support lies at ₹1,228.6 (pivot) and ₹1,216.4 (low); a break below could accelerate downside given the weak weekly structure. - [Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/ERIS_06112026144538_Signedintimation_1.pdf) - [Eris Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/ERIS_04112026164053_signedIntimation.pdf) - [Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_15266_WebXMLFile_20261104_164430997.xml) - [Eris Lifesciences Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_29102026171716_intimationsigned.pdf) - [Eris Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_29102026172141_Intimationsigned.pdf) - [Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/ERIS_26102026134804_Signedoutcome.pdf) - [Eris Lifesciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/ERIS_26102026135457_Presentationsigned.pdf) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745950_26102026050920_WEB.xml) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745951_26102026050937_WEB.xml) - [Eris Lifesciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_26102026210145_intimationsigned.pdf) ### FAQs **What corporate governance action is ERIS currently seeking from shareholders?** Eris Lifesciences is seeking shareholder approval via postal ballot to appoint Mr. Akhil Awasthi as a Non-Executive Independent Director for five consecutive years, from September 26, 2026, to September 25, 2031. Remote e-voting was active from November 6, 2026, to December 5, 2026. **How has the stock performed over different time horizons as of November 6, 2026?** As of November 6, 2026, the stock closed at ₹1,237.0 with a market capitalization of approximately ₹17,044 crore. It posted a +12.9% return over 10 days and +4.4% over one month, but remains down -17.6% year-to-date and -22.0% over the past year. **What are the key technical support and resistance levels for ERIS shares?** The nearest support level is ₹1,228.6 (0.68% below), followed by ₹1,220.37. Resistance is located at ₹1,242.1 (0.41% above) and ₹1,254.3 (1.40% above). The daily trend indicator shows a bullish supertrend direction, while the weekly trend indicates bearish momentum. **When is the next major investor engagement event scheduled?** Eris will host the 'Eris Investor Meet - 2026' on Thursday, November 19, 2026, in Mumbai. The event will be available in both physical and virtual modes, with discussions restricted to publicly available documents. - [Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/ERIS_06112026144538_Signedintimation_1.pdf) - [Eris Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/ERIS_04112026164053_signedIntimation.pdf) - [Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_15266_WebXMLFile_20261104_164430997.xml) - [Eris Lifesciences Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_29102026171716_intimationsigned.pdf) - [Eris Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_29102026172141_Intimationsigned.pdf) - [Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/ERIS_26102026134804_Signedoutcome.pdf) - [Eris Lifesciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/ERIS_26102026135457_Presentationsigned.pdf) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745950_26102026050920_WEB.xml) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745951_26102026050937_WEB.xml) - [Eris Lifesciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ERIS_26102026210145_intimationsigned.pdf) ## Technical analytics - As of: 2026-11-06 - Daily trend: Weak Uptrend - Weekly trend: Weak Downtrend - Pivot point: ₹1,228.6 - Risk regime: Higher Price Risk ### Support levels - 1220.3671875 - 1200 - 1162 ### Resistance levels - 1297.7375 - 1329.0948486328125 - 1417.375 ### Return and range metrics | Metric | Value | | --- | --- | | return_1 | +0.58% | | return_10 | +12.92% | | return_1m | +4.41% | | return_1y | -21.98% | | return_20 | +7.09% | | return_3m | -10.55% | | return_5 | +6.97% | | return_6m | -9.83% | | return_since_start | -7.08% | | return_ytd | -17.61% | ### Risk and volatility metrics | Metric | Value | | --- | --- | | state | high_risk | | label | Higher price risk | | summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. | | maximum_drawdown | -40.71% | | annualized_volatility | +32.79% | ## Quarterly financials - Latest complete quarter: fy27_q2 # Eris Lifesciences Q2 FY2026-27: Revenue up 12.6% year on year Revenue from operations rose 12.6% year on year to ₹892 crore in the quarter ended 30 September 2026, while profit before exceptional items and tax increased 11.8% to ₹193 crore. A ₹35.9 crore exceptional charge pulled profit before tax down 9.0% year on year, but a net tax benefit supported profit for the period of ₹187 crore and basic EPS of ₹13.26. ## Revenue and operating performance Revenue from operations increased 2.2% sequentially from ₹873 crore in Q1 FY2026-27 to ₹892 crore in Q2. Other income of ₹3.2 crore brought total income to ₹896 crore. Expenses rose 1.0% sequentially to ₹703 crore, slower than revenue; within this, other expenses increased 12.9% to ₹208 crore, while finance costs edged down to ₹46.4 crore. Profit before exceptional items and tax was ₹193 crore, up 7.1% from Q1 FY2026-27 and 11.8% from Q2 FY2025-26. This indicates growth in pre-exceptional earnings even as the exceptional charge weighed on reported pre-tax profit. ## Exceptional charge, tax and earnings The ₹35.9 crore exceptional charge, with no exceptional item in Q1 FY2026-27 or Q2 FY2025-26, reduced profit before tax to ₹157 crore. Profit before tax was down 12.8% sequentially and 9.0% year on year. Tax was a net benefit of ₹31.2 crore, compared with an expense of ₹36.2 crore in Q1 FY2026-27. The quarterly tax line comprised a current tax benefit of ₹64.8 crore, partly offset by deferred tax expense of ₹33.6 crore. Profit from continuing operations was ₹188 crore; total profit for the period was ₹187 crore, of which ₹183.8 crore was attributable to owners of the parent and ₹3.3 crore to non-controlling interests. Basic EPS was ₹13.26, compared with ₹10.28 in Q1 FY2026-27 and ₹8.82 in Q2 FY2025-26. The sequential increase in reported profit and EPS came alongside lower profit before tax, reflecting the net tax benefit. ## Cash flow and balance sheet Operating cash flow was ₹637 crore in Q2 FY2026-27, while investing and financing activities recorded outflows of ₹285 crore and ₹169 crore, respectively. Reported free cash flow was ₹352 crore. Cash and cash equivalents stood at ₹238 crore on 30 September 2026, up from ₹54.7 crore on 31 March 2026. Over the same dates, noncurrent borrowings declined to ₹427 crore from ₹956 crore, while current borrowings increased to ₹1,954 crore from ₹1,354 crore. Equity attributable to owners of the parent rose to ₹4,144 crore from ₹3,903 crore. ## Management commentary Management said brands contributing about ₹100 crore of sales were out-licensed to Zorvia Healthcare, with Eris retaining brand ownership and earning a 7% royalty. Excluding those brands, Q2 Domestic Branded Formulations revenue growth was 16.5%, compared with reported growth of 14.1%. DBF EBITDA margin was 35.7%, down from 37.6%, a decline of 191 basis points. Management expects the out-licensed portfolio to contribute roughly 100 basis points of gross margin improvement going forward. ## Key Takeaway Revenue and pre-exceptional profit grew year on year, but the exceptional charge drove reported profit before tax lower. The net tax benefit lifted reported earnings and EPS, while cash balances increased and the borrowing mix shifted toward current borrowings as noncurrent borrowings fell. ### Ratios ## Shareholding pattern - Quarter: FY2027-Q2 - As of: 2026-09-30 - Promoter holding: +54.74% - FII holding: +5.74% - DII holding: +20.19% - Mutual fund holding: +17.98% - Retail holding: +2.50% - Promoter pledged: +0.00% ### Major reported shareholders - Amit Indubhusan Bakshi — +42.96% - Lilac Investments Limited — +8.62% - Hdfc Small Cap Fund — +8.19% - Rajendrakumar Rambhai Patel — +4.28% - Inderjeet Singh Negi — +4.28% - Franklin India Small Cap Fund — +3.76% - Kaushal Kamleshkumar Shah — +3.22% - Hetal Rasiklal Shah — +2.12% - Bhikhalal Chimanlal Shah — +1.93% - Naishadh Vikram Shah — +1.66% ## Official filings - 2026-11-06 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_06112026144538_Signedintimation_1.pdf) - 2026-11-04 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_04112026164053_signedIntimation.pdf) - 2026-11-04 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_15266_WebXMLFile_20261104_164430997.xml) - 2026-10-29 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_29102026171716_intimationsigned.pdf) - 2026-10-29 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_29102026172141_Intimationsigned.pdf) - 2026-10-26 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_26102026134804_Signedoutcome.pdf) - 2026-10-26 — Earnings Presentation: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_26102026135457_Presentationsigned.pdf) - 2026-10-26 — Financial Results Filing: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745950_26102026050920_WEB.xml) - 2026-10-26 — Financial Results Filing: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745951_26102026050937_WEB.xml) - 2026-10-26 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_26102026210145_intimationsigned.pdf) - 2026-10-19 — Shareholding Disclosure: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1741191_19102026120426_WEB.xml) - 2026-10-19 — Board Meeting Notice: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_15266_WebXMLFile_20261019_181829364.xml) - 2026-10-19 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_15266_WebXMLFile_20261019_181829364.xml) - 2026-10-19 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_15266_WebXMLFile_20261019_183409742.xml) - 2026-10-19 — Board Meeting Notice: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_19102026183711_SE_intimationsigned.pdf) - 2026-10-19 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_19102026183848_Intimationsigned.pdf) - 2026-10-07 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_07102026175020_Intimationsigned.pdf) - 2026-10-05 — Management Change: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_05102026115735_Intimationsigned.pdf) - 2026-09-28 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_28092026173228_TWCsigned.pdf) - 2026-09-28 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_15266_WebXMLFile_20260928_173627340.xml) - 2026-09-28 — Generic Announcement: Exim Routes Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EXIM_28092026232628_MOU_ALSAHEED-EXIM_ERIS_Signed.pdf) - 2026-09-25 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_25092026115141_Proceedings_of_AGM.pdf) - 2026-09-25 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_25092026192837_signed.pdf) - 2026-09-25 — Regulatory Filing: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1728640_25092026073529_WEB.xml) - 2026-09-22 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_22092026164321_Intimationsigned.pdf) ## News and market events - 2026-10-27 — CNBC-TV18: **Eris Lifesciences expects 150-200 basis point gross margin expansion in second half as biologics scale up** — Eris Lifesciences expects profitability to improve as biologics production ramps up and acquired businesses continue to scale. The company also expects India's semaglutide market to grow significantly over the next year while planning faster debt reduction as its capex cycle slows. — [Source](https://www.cnbctv18.com/market/earnings/eris-lifesciences-expects-150-200-bps-margin-improvement-in-h2-as-biologics-scale-up-q2-earnings-results-boardroom-semaglutide-diabetes-glp-1-20020202.htm) - 2026-10-27 — MONEYCONTROL: **Buy Eris Lifesciences; target of Rs 1500: Prabhudas Lilladher** — Buy Eris Lifesciences; target of Rs 1500: Prabhudas Lilladher Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio IPO Allotment Jio IPO Listing Date Israel Elections 2026 live Microsoft Buyout news Gyanesh Kumar Benjamin Netanyahu Noel Tata Ather Share Price Anthropic IPO News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX Price Gold MCX Price Personal Finance more Home Loa — [Source](https://www.moneycontrol.com/news/business/earnings/buy-eris-lifesciences-target-of-rs-1500-prabhudas-lilladher-14061105.html) - 2026-09-29 — BUSINESS: **Volumes spurt at Honasa Consumer Ltd counter** — Honasa Consumer Ltd notched up volume of 196.48 lakh shares by 14:14 IST on NSE, a 26.53 fold spurt over two-week average daily volume of 7.41 lakh shares — [Source](https://www.business-standard.com/markets/capital-market-news/volumes-spurt-at-honasa-consumer-ltd-counter-126092900671_1.html) - 2026-09-22 — BUSINESSTODAY: **Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare** — Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare — [Source](https://www.businesstoday.in/industry/pharma/story/heres-why-chryscapital-expects-20-25-of-the-latest-2-2-billion-fund-to-go-to-pharma-healthcare-557090-2026-09-22) - 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html) - 2026-09-11 — MONEYCONTROL: **Eris Lifesciences COO V Krishnakumar steps down, set to join Biological E** — V Krishnakumar, Eris Lifesciences, Biological E, BE BioSol, Eris Lifesciences COO, Biological E CEO, CDMO business, biopharma, vaccine manufacturers, pharma leadership, Krishnakumar resignation, Eris Lifesciences resignation — [Source](https://www.moneycontrol.com/news/business/eris-lifesciences-coo-v-krishnakumar-steps-down-set-to-join-biological-e-14028078.html) - 2026-09-08 — Economic Times: **Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake** — Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/tata-capital-healthcare-fund-to-exit-linux-laboratories-as-chryscapital-buys-20-25-stake/articleshow/133939441.cms) - 2026-08-06 — The Hindu: **Sensex today | Stock Market Live: Sensex rises 250 pts, Nifty holds 24,600 on US-Iran peace hopes, RBI outlook; Neuland Lab shares up 9.6%** — Sensex, Nifty, Share Prices LIVE: Sensex was up 160.95 pts or 0.20% to 78,741.95 at 9.16 am after opening at 78,782.43 from the previous close of 78,581; Nifty inched up 8.70 pts or 0.04% to 24,633.35. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-6-august-2026/article71309748.ece) - 2026-07-29 — CNBC-TV18: **Eris Lifesciences' Q1 profit jumps 21%, but margins come under pressure** — The drugmaker reported double-digit growth in revenue and profit for the June quarter, even as rising costs squeezed operating margins. — [Source](https://www.cnbctv18.com/market/eris-lifesciences-q1-pat-up-21-pc-shares-gain-2-pc-after-results-19956646.htm) - 2026-07-29 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty surges 260 points; Kaynes Tech up 12%** — Sensex Today | Stock Market LIVE Updates: We are the halfway mark of the day's trade, and the bulls look in a strong position. The markets are on the rise, and are trading on a strong footing. The Nifty up over 240 points, jumping to 24,200. The Nifty Bank index is up 400 points, rising to 57,000. Infosys, Larsen & Toubro and HUL are the top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-hul-asian-paints-adani-oil-lt-grse-it-dmart-share-price-liveblog-19956206.htm) ## Business profile **Strategic vision:** Pharmaceutical company developing and marketing branded formulations for chronic diseases. ### Business segments - **Cardio-Metabolic:** Focuses on addressing chronic and sub-chronic diseases, with a core presence in the cardio-metabolic therapeutic area. - **Anti-Diabetes:** Includes oral anti-diabetic medications and insulin products. - **Cardiovascular Care:** Products aimed at managing cardiovascular health. - **Vitamins, Minerals, and Nutrition (VMN):** Nutritional supplements and products. - **Emerging Therapeutic Areas:** Expanding into dermatology, gynaecology, neuroscience, nephrology, oncology, and critical care. - **Injectables:** Segment includes sterile injectables, acquired through Swiss Parenterals, and branded injectables in critical care. - **Oncology:** Entry into the oncology segment with a portfolio of monoclonal antibodies. ### Competitive strengths - Vertically integrated pharmaceutical operations with WHO-GMP approved manufacturing facilities. - Extensive distribution network across India. - Strategic acquisitions to expand into new therapeutic areas and product segments. ## Related stocks - [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30% - [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23% - [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64% - [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56% - [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64% ## Freshness and sources - Data as of: 2026-11-06 - Source: Faxioms public stock analysis API Canonical: https://faxioms.com/stocks/eris Markdown representation: https://faxioms.com/stocks/eris?render=md